Apotex Pharmachem Inc.

Apotex Inc.

Yajun Zhao

Daqing Che

Allan W Rey

Bhaskar Reddy Guntoori

Fan Wang

Uma Kotipalli

Gamini Weeratunga

Stuart P Green

Sammy Chris Duncan

Minh T N Nguyen

K S Keshava Murthy

Cameron L McPhail

Mohammed Abdul Raheem

Peter Garth Blazecka

Aaron C Kinsman

Jody Faught

Alan Chow

Craig Stewart

Fabio E S Souza

Stephen E Horne

Alexander J Stirk

Probal Kanti Datta

David A Stradiotto

Murali Kondamreddy

Ks Keshava Murthy

Michael B Johansen

Siva Ramarao Kakani

Prabhudas Bodhuri

Bruno K Radatus

Carlos Zetina-Rocha

Kiran Kumar Kothakonda

Alfredo Paul Ceccarelli

Jenny L Gerster

Michael R Emmett

Eduardo Gustavo Cammisa

Laura Kaye Montemayor

Nageib Mohamed

Mohamed Ibrahim Zaki

Kaarina K Milnes

Kevin Wade Kells

Nalini Nagireddy

Tania E Nish

Fatemeh Mohammadpourmir

Randa E El-Haj

The present invention provides novel crystalline forms of zuclomiphene citrate. Specific crystalline forms provided by the present invention include zuclomiphene citrate Forms APO-I, APO-II, APO-III, and APO-IV. Also provided are pharmaceutical compositions including the zuclomiphene citrate crystalline forms, processes for the preparation thereof and the use of these forms in the treatment of a disorder selected from the group including osteoporosis, bone fractures, loss of bone mineral density (BMD) and hot flashes in a subject suffering therefrom.

Crystalline forms of zuclomiphene citrate

The present invention provides zuclomiphene salts, zuclomiphene binaphthyl hydrogen phosphate salt (1-A)&#xb7;(BPA) and zuclomiphene oxalate salt (1-A)&#xb7;(OXL), crystalline forms thereof and processes for the preparation thereof.

Zuclomiphene salts and crystalline forms thereof

The present invention provides a novel crystalline form of Valbenazine dibesylate, Valbenazine dibesylate Form APO-I, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of hyperkinetic disorders, including tardive dyskinesia.

Crystalline form of Valbenazine dibesylate

The present invention provides processes for the preparation of Tezacaftor, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (3), and its conversion to Tezacaftor (1). 

Processes for the preparation of Tezacaftor and intermediates thereof

The present invention provides processes for the preparation of Tasimelteon (1), as well as processes for the preparation of intermediates of Formulas (2), (3) and (4) useful in the preparation of Tasimelteon (1). 

Processes for the preparation of Tasimelteon and intermediates thereof

This invention provides processes for preparation of 3-alkyl indoles of Formula 1: wherein A, Aand Aare independently selected from the group consisting of: H, X, OR, CN, CONRand C0R; Ris C-Calkyl; Ris H or C-Calkyl; Ris C-Calkyl; LG is a leaving group; X is a halogen; and n is 1, 2 or 3.

Processes for the preparation of 3-alkyl indoles

Vilazodone hydrochloride benzyl alcohol solvates are provided as well as processes for the preparation thereof.

Forms of vilazodone and processes for the preparation thereof

There is provided processes for preparing Lubiprostone and intermediates thereof. Also provided are compounds, including intermediates for preparing Lubiprostone as well compositions comprising Lubiprostone and other compounds, including intermediates for preparing Lubiprostone and other compounds. (I) 

Methods of making lubiprostone and intermediates thereof

Disclosed are solid forms of Nilotinib hydrochloride and methods of preparation of various crystalline solvates of Nilotinib HCl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (CML).

Solid forms of nilotinib hydrochloride

Provided for in the instant application are two additional forms of rifaximin, namely rifaximin polymorphic forms APO-III and APO-IV. Also provided are allegedly novel processes for preparing the previously disclosed rifaximin polymorphic forms APO-I and APO-II. Rifaximin is a non-aminoglycoside antibiotic that has previously been found to be useful for the treatment of traveller's diarrhea caused bybacteria, as well as in the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections and as an antibacterial prophylactic prior to colon surgery.

Polymorphic forms of rifaximin

This invention relates to 1,3-oxathiolane derivatives (I), processes for the preparation of 1,3-oxathiolane derivatives and intermediate compounds thereof. 

1,3-Oxathiolane derivatives, process for the preparation of 1,3-Oxathiolane derivatives and intermediates thereof

Atorvastatin calcium propylene glycol solvates and processes to prepare these novel solvates which are particularly useful and suitable for pharmaceutical applications.

Atorvastatin calcium propylene glycol solvates

A process is provided for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 comprising:    

Process for the preparation of atorvastatin and intermediates

A process is provided for preparing pharmaceutical grade atorvastatin hemicalcium salt comprising:  

Process for producing atorvastatin hemicalcium

Growing community of inventors

Brantford, Canada

Yajun Zhao